Specificity of the HIV-1 Protease on Substrates Representing the Cleavage Site in the Proximal Zinc-Finger of HIV-1 Nucleocapsid Protein.


Journal

Viruses
ISSN: 1999-4915
Titre abrégé: Viruses
Pays: Switzerland
ID NLM: 101509722

Informations de publication

Date de publication:
08 06 2021
Historique:
received: 26 04 2021
revised: 02 06 2021
accepted: 03 06 2021
entrez: 2 7 2021
pubmed: 3 7 2021
medline: 17 8 2021
Statut: epublish

Résumé

To explore the sequence context-dependent nature of the human immunodeficiency virus type 1 (HIV-1) protease's specificity and to provide a rationale for viral mutagenesis to study the potential role of the nucleocapsid (NC) processing in HIV-1 replication, synthetic oligopeptide substrates representing the wild-type and modified versions of the proximal cleavage site of HIV-1 NC were assayed as substrates of the HIV-1 protease (PR). The S1' substrate binding site of HIV-1 PR was studied by an in vitro assay using KIVKCF↓NCGK decapeptides having amino acid substitutions of N17 residue of the cleavage site of the first zinc-finger domain, and in silico calculations were also performed to investigate amino acid preferences of S1' site. Second site substitutions have also been designed to produce "revertant" substrates and convert a non-hydrolysable sequence (having glycine in place of N17) to a substrate. The specificity constants obtained for peptides containing non-charged P1' substitutions correlated well with the residue volume, while the correlation with the calculated interaction energies showed the importance of hydrophobicity: interaction energies with polar residues were related to substantially lower specificity constants. Cleavable "revertants" showed one residue shift of cleavage position due to an alternative productive binding mode, and surprisingly, a double cleavage of a substrate was also observed. The results revealed the importance of alternative binding possibilities of substrates into the HIV-1 PR. The introduction of the "revertant" mutations into infectious virus clones may provide further insights into the potential role of NC processing in the early phase of the viral life-cycle.

Identifiants

pubmed: 34201134
pii: v13061092
doi: 10.3390/v13061092
pmc: PMC8227227
pii:
doi:

Substances chimiques

Nucleocapsid Proteins 0
Recombinant Proteins 0
HIV Protease EC 3.4.23.-

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Références

J Virol. 2005 Apr;79(7):4213-8
pubmed: 15767422
PLoS One. 2020 Jan 9;15(1):e0227062
pubmed: 31917798
J Biol Chem. 1997 Jul 4;272(27):16807-14
pubmed: 9201986
J Biol Chem. 1994 Sep 2;269(35):21948-50
pubmed: 8071314
Biochemistry. 2006 Oct 17;45(41):12617-28
pubmed: 17029416
Biochemistry. 2004 Apr 13;43(14):4304-12
pubmed: 15065874
J Virol. 2005 Jun;79(12):7756-67
pubmed: 15919928
Anal Biochem. 2018 Jan 1;540-541:52-63
pubmed: 29122614
Res Virol. 1992 Sep-Oct;143(5):311-9
pubmed: 1480823
J Virol. 2000 Feb;74(3):1168-77
pubmed: 10627527
Antiviral Res. 1997 Nov;36(2):107-13
pubmed: 9443667
Virology. 2006 Oct 25;354(2):261-70
pubmed: 16904152
FEBS Lett. 1991 Feb 25;279(2):356-60
pubmed: 2001747
Biochemistry. 1993 Apr 6;32(13):3347-53
pubmed: 8384879
J Cell Sci. 1995 Sep;108 ( Pt 9):3039-50
pubmed: 8537443
Antiviral Res. 2001 Feb;49(2):101-14
pubmed: 11248362
J Virol. 1992 Aug;66(8):5087-91
pubmed: 1378515
J Vis Exp. 2019 Jan 16;(143):
pubmed: 30735187
Biochem Biophys Res Commun. 1991 Aug 30;179(1):17-24
pubmed: 1652947
Proteins. 2002 Jul 1;48(1):107-16
pubmed: 12012342
Virus Res. 2008 Jun;134(1-2):39-63
pubmed: 18279991
Virology. 2008 Jun 5;375(2):592-610
pubmed: 18343475
J Gen Virol. 2006 Apr;87(Pt 4):961-965
pubmed: 16528046
J Virol. 1993 Oct;67(10):6159-69
pubmed: 8371356
J Comput Chem. 1986 Apr;7(2):230-252
pubmed: 29160584
Biochemistry. 1992 May 26;31(20):4793-800
pubmed: 1591240
J Virol. 1994 Feb;68(2):757-65
pubmed: 8289379
Arch Biochem Biophys. 1991 Oct;290(1):186-90
pubmed: 1898088
J Virol. 2008 Oct;82(20):10111-7
pubmed: 18701588
Prog Biophys Mol Biol. 1972;24:107-23
pubmed: 4566650
Biochem Biophys Res Commun. 1989 Apr 28;160(2):486-94
pubmed: 2541703
Antimicrob Agents Chemother. 2012 Aug;56(8):4381-90
pubmed: 22664974
Data Brief. 2018 Mar 12;18:203-208
pubmed: 29896511
Curr Pharm Des. 2003;9(22):1803-15
pubmed: 12871198
Eur J Biochem. 2000 Oct;267(20):6287-95
pubmed: 11012683
Curr Top Med Chem. 2003;3(13):1447-57
pubmed: 14529520
J Virol. 1996 Sep;70(9):5840-4
pubmed: 8709202
Protein Eng. 1991 Aug;4(6):695-700
pubmed: 1658777
Biochem Biophys Res Commun. 1990 Jun 29;169(3):1111-6
pubmed: 2114105
Trends Biochem Sci. 1998 Aug;23(8):297-301
pubmed: 9757830

Auteurs

János András Mótyán (JA)

Laboratory of Retroviral Biochemistry, Department of Biochemistry and Molecular Biology, Faculty of Medicine, University of Debrecen, 4032 Debrecen, Hungary.

Márió Miczi (M)

Laboratory of Retroviral Biochemistry, Department of Biochemistry and Molecular Biology, Faculty of Medicine, University of Debrecen, 4032 Debrecen, Hungary.
Doctoral School of Molecular Cell and Immune Biology, University of Debrecen, 4032 Debrecen, Hungary.

Stephen Oroszlan (S)

HIV Dynamics and Replication Program, National Cancer Institute, Frederick, MD 21702, USA.

József Tőzsér (J)

Laboratory of Retroviral Biochemistry, Department of Biochemistry and Molecular Biology, Faculty of Medicine, University of Debrecen, 4032 Debrecen, Hungary.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH